Table 6.
Gender differences in TNFi treatment response and adherence
| Study | AS or axSpA | Study design | M/F | Treatment response M/F | TNF naive population | Follow-up period |
|---|---|---|---|---|---|---|
| Lubrano, 2017 [63] | axSpA | Retrospective | 228/93 | ASAS40%: ↑ response male*‡ | Yes | Every 3 months |
| Rusman, 2017 [88] | AS | Prospective observational cohort | 194/97 | BASDAI50%: 62%/43%* BASDAI50%: 59%/46%* ASDAS: 64.9%/47.6%* ASDAS: 65.9%/46.3%* |
Yes | 12 months 24 months 6 months 12 months |
| Lorenzin, 2015 [31] | AS | Retrospective | 52/18 | ASAS20: 82.9%/65.7% | n.a. | 60 months |
| Gremese, 2013 [23] | axSpA | Retrospective | 118/52 | BASDAI50%: 67.8%/46.2%* | Yes | 12 months |
| Horst-Bruinsma, 2012 [26••] | AS | Pooled data clinical controlled trials | 957/326 | ASDAS: 89.4%/68.4%* | Yes | 12 weeks |
| Paccou, 2012 [32] | AS | Retrospective | 121/68 | BASDAI50%: 78.5%/21.5%* | Yes | 3 months |
| Arends, 2011 [28] | AS | Prospective longitudinal observational | 152/68 | ASAS20: ↑ response Male*‡ ASAS40: ↑ response Male*‡ |
Yes | 3 and 6 months 6 months |
| Glintborg, 2010 [27] | AS | Observational cohort | 364/239 | Change in BASDAI: 27/22 | Yes | 6 months |
| Study | AS or axSpA | Study design | M/F | Treatment adherence | Study time period | |
| Rusman, 2016 [89] | AS | Prospective cohort | 74/48 | Males: 44.9 months Females: 33.4 months |
Mean 4.8 years | |
| Horst-Bruinsma, 2012 [26••] | AS | Pooled data clinical controlled trials | 957/326 | ↓ Females: HR: 1.5 | 12 weeks | |
| Glintborg, 2013 [90] | AS | Observational cohort | 1076/360 | ↑ Males: HR:1.76 | 10 years | |
| Arends, 2011 [28] | AS | Prospective longitudinal observational | 152/68 | ↓ Females: HR:0.41 | 6 months | |
| Glintborg, 2010 [27] | AS | Observational cohort | 364/239 | ↓Females: HR:3.4 | 5 years | |
| Kristensen, 2010 [30] | AS | Prospective observational cohort | 182/61 | ↑Males: HR:0.36 | 2 years | |
| Pavelka, 2009 [33] | AS | Prospective observational | 238/72 | ↓Females: RR: 2.2 | 2 years | |
Treatment adherence = time on TNFi
AS ankylosing spondylitis, axSpA axial spondyloarthritis, ASAS20 ASAS response criteria, ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Score, BASDAI50% response op de BASDAI 50%, TNF naive no earlier use of TNFi treatment before study, HR hazard ratio
*Significant gender difference